William R Hiatt

Summary

Affiliation: University of Colorado Denver
Country: USA

Publications

  1. doi request reprint Pathogenesis of the limb manifestations and exercise limitations in peripheral artery disease
    William R Hiatt
    From the Division of Cardiology, Department of Medicine W R H, E J A, CPC Clinical Research W R H, University of Colorado School of Medicine, Aurora Cardiovascular and Metabolic Diseases Drug Discovery Unit, Takeda Pharmaceuticals, San Diego, CA C J L and Department of Medicine, Harbor UCLA Center for Clinical Pharmacology, Torrance, CA E P B
    Circ Res 116:1527-39. 2015
  2. doi request reprint A validated biomarker panel to identify peripheral artery disease
    William R Hiatt
    University of Colorado School of Medicine, Division of Cardiology, Aurora, CO 80045, USA
    Vasc Med 17:386-93. 2012
  3. doi request reprint Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease
    William R Hiatt
    University of Colorado School of Medicine, Division of Cardiology and CPC Clinical Research, Aurora, Colorado 80045, USA
    J Cardiopulm Rehabil Prev 31:125-32. 2011
  4. pmc Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training
    W Schuyler Jones
    Division of Cardiology, Duke University Medical Center, Durham, NC, USA
    Vasc Med 17:94-100. 2012
  5. doi request reprint The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program
    Judith G Regensteiner
    Department of Medicine, University of Colorado School of Medicine, Denver, CO 80262, USA
    Vasc Med 13:15-24. 2008
  6. doi request reprint Association of clinical attributes and treadmill walking performance in patients with claudication due to peripheral artery disease
    Eric P Brass
    Harbor University of California Los Angeles UCLA Center for Clinical Pharmacology, Torrance, CA, USA
    J Vasc Surg 58:396-403. 2013
  7. doi request reprint A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication
    Eric P Brass
    Harbor UCLA Center for Clinical Pharmacology, Torrance, CA 90502, USA
    J Vasc Surg 55:381-389.e1. 2012
  8. pmc Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease
    Jennifer L Robbins
    Department of Medicine, Division of Cardiology, Duke University Medical Center, Box 3126, Durham, NC 27710, USA
    J Appl Physiol (1985) 111:81-6. 2011
  9. pmc Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients
    Brian D Duscha
    Duke University Medical Center, Division of Cardiology, Durham, NC 27710, USA
    Arterioscler Thromb Vasc Biol 31:2742-8. 2011
  10. pmc Assessment of functional status and quality of life in claudication
    Ryan J Mays
    Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA
    J Vasc Surg 53:1410-21. 2011

Detail Information

Publications35

  1. doi request reprint Pathogenesis of the limb manifestations and exercise limitations in peripheral artery disease
    William R Hiatt
    From the Division of Cardiology, Department of Medicine W R H, E J A, CPC Clinical Research W R H, University of Colorado School of Medicine, Aurora Cardiovascular and Metabolic Diseases Drug Discovery Unit, Takeda Pharmaceuticals, San Diego, CA C J L and Department of Medicine, Harbor UCLA Center for Clinical Pharmacology, Torrance, CA E P B
    Circ Res 116:1527-39. 2015
    ....
  2. doi request reprint A validated biomarker panel to identify peripheral artery disease
    William R Hiatt
    University of Colorado School of Medicine, Division of Cardiology, Aurora, CO 80045, USA
    Vasc Med 17:386-93. 2012
    ..The model also performed well in subjects with no prior history of PAD. Thus, a biomarker panel may have a role for identifying PAD...
  3. doi request reprint Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease
    William R Hiatt
    University of Colorado School of Medicine, Division of Cardiology and CPC Clinical Research, Aurora, Colorado 80045, USA
    J Cardiopulm Rehabil Prev 31:125-32. 2011
    ..This trial tested the hypothesis that propionyl-L-carnitine (PLC), in combination with monitored home-based exercise training, would improve treadmill peak walking time (PWT) over exercise training alone...
  4. pmc Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training
    W Schuyler Jones
    Division of Cardiology, Duke University Medical Center, Durham, NC, USA
    Vasc Med 17:94-100. 2012
    ..These somewhat unexpected findings suggest that further investigation into the mechanism of vascular responses to exercise training in PAD patients is warranted...
  5. doi request reprint The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program
    Judith G Regensteiner
    Department of Medicine, University of Colorado School of Medicine, Denver, CO 80262, USA
    Vasc Med 13:15-24. 2008
    ....
  6. doi request reprint Association of clinical attributes and treadmill walking performance in patients with claudication due to peripheral artery disease
    Eric P Brass
    Harbor University of California Los Angeles UCLA Center for Clinical Pharmacology, Torrance, CA, USA
    J Vasc Surg 58:396-403. 2013
    ..This study evaluated factors suspected to be correlated with treadmill walking performance in an effort to gain insights into the pathophysiology of the impairment...
  7. doi request reprint A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication
    Eric P Brass
    Harbor UCLA Center for Clinical Pharmacology, Torrance, CA 90502, USA
    J Vasc Surg 55:381-389.e1. 2012
    ..K-134, a novel phosphodiesterase inhibitor, was evaluated in a phase II trial incorporating an adaptive design to assess its safety, tolerability, and effect on treadmill walking time...
  8. pmc Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease
    Jennifer L Robbins
    Department of Medicine, Division of Cardiology, Duke University Medical Center, Box 3126, Durham, NC 27710, USA
    J Appl Physiol (1985) 111:81-6. 2011
    ..These findings suggest that alterations in microcirculation may contribute to functional impairment capacity in PAD...
  9. pmc Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients
    Brian D Duscha
    Duke University Medical Center, Division of Cardiology, Durham, NC 27710, USA
    Arterioscler Thromb Vasc Biol 31:2742-8. 2011
    ..This study tested the hypothesis that in PAD patients who undergo supervised exercise training, increases in capillary density (CD) in calf muscle take place before improvements in peak oxygen uptake (VO(2))...
  10. pmc Assessment of functional status and quality of life in claudication
    Ryan J Mays
    Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA
    J Vasc Surg 53:1410-21. 2011
    ..Although this is an important measure, it does not provide information about how patients perceive the effects of their treatments on more global measures of health-related quality of life (HRQOL)...
  11. doi request reprint Clinical outcomes using aggressive approach to anatomic screening and endovascular revascularization in a veterans affairs population with critical limb ischemia
    Alap P Shah
    Department of Medicine, University of Colorado Denver, Aurora, Colorado, USA
    Catheter Cardiovasc Interv 74:11-9. 2009
    ....
  12. doi request reprint L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial
    Neil A Goldenberg
    Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, CO 80045, USA
    Vasc Med 17:145-54. 2012
    ..145 for cilostazol/placebo (p = 0.048). QOL measures were also improved in the cilostazol/l-carnitine group. These findings support larger trials of l-carnitine in combination with cilostazol in the treatment of IC...
  13. doi request reprint A randomized trial of iloprost in patients with intermittent claudication
    Mark A Creager
    Department of Medicine, Division of Cardiology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Vasc Med 13:5-13. 2008
    ..039). Neither iloprost nor pentoxifylline enhanced quality of life. These results indicate that oral iloprost is not effective in improving exercise performance or quality of life in patients with PAD who have intermittent claudication...
  14. ncbi request reprint The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease
    Eric P Brass
    Department of Medicine, Harbor UCLA Medical Center, Torrance, California 90502, USA
    J Am Coll Cardiol 48:2539-45. 2006
    ..The current study tested the hypothesis that NM-702 improves treadmill exercise performance in peripheral arterial disease patients with claudication-limited exercise performance...
  15. ncbi request reprint Peripheral arterial disease rehabilitation: a review
    Rita A Falcone
    Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Cardiopulm Rehabil 23:170-5. 2003
  16. ncbi request reprint Skeletal muscle metabolic changes in peripheral arterial disease contribute to exercise intolerance: a point-counterpoint discussion
    Eric P Brass
    Center for Clinical Pharmacology, Department of Medicine, Harbor UCLA Medical Center, Torrance, CA, USA
    Vasc Med 9:293-301. 2004
    ..The relative contribution of these factors and their role in the pathophysiology of the exercise limitation is discussed using a point-counterpoint approach. Future directions for research conclude the discussion...
  17. ncbi request reprint Increased levels of apoptosis in gastrocnemius skeletal muscle in patients with peripheral arterial disease
    Robert G Mitchell
    Division of Cardiology, Department of Medicine, Durham VA and Duke University Medical Center, Durham, NC 27710, USA
    Vasc Med 12:285-90. 2007
    ..53% +/- 0.96; p < 0.001). In conclusion, PAD is associated with increased levels of apoptosis in the peripheral skeletal muscle. Further study is required to ascertain whether apoptosis plays a role in decreased functional capacity...
  18. ncbi request reprint Peripheral arterial disease is not associated with an increased prevalence of intradialytic cramps in patients on maintenance hemodialysis
    Eric P Brass
    Department of Medicine, Harbor UCLA Medical Center, Torrance, Calif 90502, USA
    Am J Nephrol 22:491-6. 2002
    ..Peripheral arterial disease (PAD) has been suggested as a contributing factor to the development of intradialytic muscle cramps in patients on maintenance hemodialysis...
  19. ncbi request reprint Risk assessment in the patient with established peripheral arterial disease
    Scott Haugen
    Divisions of Cardiology and General Internal Medicine, Department of Medicine, University of Colorado School of Medicine, Denver, CO, USA
    Vasc Med 12:343-50. 2007
    ..Defining which patients are in the highest category of risk may direct health care providers to emphasize secondary preventive measures, and facilitate patient adherence to recommended medical therapies and smoking cessation...
  20. pmc Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication
    Roger J Lewis
    Department of Emergency Medicine, Harbor UCLA Medical Center, 1000 West Carson Street, Torrance, California 90509, USA
    Trials 12:134. 2011
    ..We describe the design, oversight, and implementation of an adaptive, phase II, dose-finding trial evaluating K-134 for the treatment of stable, intermittent claudication...
  21. ncbi request reprint Exercise training for claudication
    Kerry J Stewart
    Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
    N Engl J Med 347:1941-51. 2002
  22. doi request reprint A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudication
    Eric P Brass
    Harbor UCLA Center for Clinical Pharmacology, Torrance, CA, USA
    Vasc Med 18:3-12. 2013
    ..In conclusion, oral PLC is associated with a statistically significant increase in PWD in patients with claudication, which may be clinically relevant...
  23. ncbi request reprint Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies
    Eric P Brass
    Harbor UCLA Center for Clinical Pharmacology, 1124 W Carson Street, Torrance, CA 90502, USA
    Vasc Med 11:141-5. 2006
    ..The current analyses provide benchmark data for ensuring that development programs are large enough to allow meaningful safety conclusions, and to assist in data and safety monitoring of these trials...
  24. doi request reprint Patterns of artery disease in 450 patients undergoing revascularization for critical limb ischemia: implications for clinical trial design
    Carlos A Rueda
    University of Colorado Health Sciences Center, Aurora, CO 80045, USA
    J Vasc Surg 47:995-9; discussion 999-1000. 2008
    ..The pattern and distribution of arterial occlusions and stenoses in patients with critical limb ischemia presenting at two academic medical centers was described...
  25. ncbi request reprint Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy
    William R Hiatt
    Department of Medicine, University of Colorado School of Medicine, Section of Vascular Medicine, and the Colorado Prevention Center, Denver, CO 80203, USA
    Vasc Med 9:18-25. 2004
    ..These data indicate that selective serotonin receptor blockade does not improve exercise tolerance or quality of life in individuals with claudication...
  26. ncbi request reprint Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia
    Eric P Brass
    Harbor UCLA Medical Center for Clinical Pharmacology, Torrance, California 90502, USA
    J Vasc Surg 43:752-9. 2006
    ..The current trial was designed to test the hypothesis that lipo-ecraprost would improve amputation-free survival in patients with CLI who had no revascularization options...
  27. pmc Community walking programs for treatment of peripheral artery disease
    Ryan J Mays
    Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colo Center for Women s Health Research, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colo Electronic address
    J Vasc Surg 58:1678-87. 2013
    ..This review evaluated the various methods and outcomes of community walking programs for PAD...
  28. doi request reprint Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials
    Jeffrey S Berger
    Department of Medicine, Division of Cardiology, New York University School of Medicine, New York, NY 10016, USA
    Am Heart J 162:115-24.e2. 2011
    ..The benefit of aspirin to prevent cardiovascular events in subjects without clinical cardiovascular disease relative to the increased risk of bleeding is uncertain...
  29. ncbi request reprint Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudication
    William R Hiatt
    Department of Medicine, University of Colorado School of Medicine, Section of Vascular Medicine, Divisions of Geriatrics and Cardiology, Denver, Colorado 80203, USA
    Vasc Med 11:55-60. 2006
    ..The use of aspirin as well as more potent antiplatelet therapies such as thienopyridines holds promise for reducing atherothrombosis in this very high-risk population...
  30. doi request reprint The "parallel-cohort RCT": Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism
    Neil A Goldenberg
    Dept of Pediatrics, Section of Hematology Oncology Bone Marrow Transplantation and Mountain States Regional Hemophilia and Thrombosis Center, Univ of Colorado Denver and The Children s Hospital, Aurora, CO, USA
    Contemp Clin Trials 31:131-3. 2010
    ....
  31. pmc Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting
    David P Kao
    Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA
    Pharmacotherapy 32:767-71. 2012
    ..To characterize the frequency and type of cardiac events, including torsade de pointes, associated with dronedarone and its structural analog, amiodarone, outside of the clinical trial setting...
  32. ncbi request reprint Pharmacologic therapy for peripheral arterial disease and claudication
    William R Hiatt
    Department of Medicine, University of Colorado School of Medicine, c o Colorado Prevention Center, 789 Sherman Street, Suite 200, Denver, CO 80203, USA
    J Vasc Surg 36:1283-91. 2002
    ....
  33. ncbi request reprint Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial
    Robert W Schrier
    Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Denver, CO 80262, USA
    Nat Clin Pract Nephrol 3:428-38. 2007
    ..Analysis of the results of 5 years of follow-up revealed a highly significant correlation of all-cause and cardiovascular mortality with left ventricular mass and severity of albuminuria...
  34. ncbi request reprint Clinical and demographic predictors of exercise capacity in end-stage renal disease
    Kathy E Sietsema
    Department of Medicine, Harbor UCLA Research and Education Institute, Torrance, CA, USA
    Am J Kidney Dis 39:76-85. 2002
    ....
  35. pmc Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model
    Neil A Goldenberg
    Department of Medicine, Section of Hematology Oncology, University of Colorado, Aurora, CO, USA
    Blood 117:2089-92. 2011
    ..Although numerous models can be entertained, the ARO-CRO model is uniquely structured to meet the demand for greater assurance of integrity in clinical trials and the needs of each stakeholder in the process...